HORNBACH Baumarkt Selects Blue Yonder To Accelerate Its Omni-Channel, Customer-Centric Strategy
19.9.2024 10:00:00 EEST | Business Wire | Press release
Today, retail offers a wide range of opportunities. Retailers must consistently focus on the needs of their customers if they want to be successful – even in the future. Tech innovation is accelerating. Consumers want to be free to decide whether they want to shop in the store or via smartphone or computer. Optimally, it should all be connected. Retailers are looking to innovate, add new services, and deliver experiences that consumers love, but they often face a costly and expensive fix because their tech stack was not built for modern experiences with efficiency in mind.
That’s why, as a pioneer in innovation and one of the leading DIY retailers in Europe, HORNBACH Baumarkt has selected Blue YonderInventory and Commits Services, part of Blue Yonder Order Management solutions.
HORNBACH Baumarkt is the largest and most important subsidiary of HORNBACH Holding. HORNBACH Baumarkt operates DIY megastores with garden centers and online stores in nine European countries. The DIY retail segment accounts for around 94% of consolidated sales for the company, with nearly half of these sales generated in Germany. Measured in terms of productivity, HORNBACH Baumarkt is the No. 1 DIY retailer in Germany by sales per square meter of sales area, based on the calculation principles of the BHB branch organization. In addition to its in-store business, the retailer has an online business, including click & collect, which accounts for around 13% of total sales. The DIY retailer offers an average of 50,000 items at its stationary stores and up to 290,000 items online.
Given the strong customer-first culture of the company and the strategic relevance of its online sales, HORNBACH Baumarkt decided to optimize the omni-channel order experience from search through purchase and delivery. By engaging customers with reliable information at the beginning of the shopping journey, HORNBACH Baumarkt will increase conversion and deliver more satisfying shopping experiences.
HORNBACH Baumarkt chose Blue Yonder because of its differentiated approach to optimizing omni-channel operations, the deep understanding of the order process, and the unique vision and strategy for the future of the supply chain.
Blue Yonder Inventory and Commits Services will allow HORNBACH Baumarkt to:
- Empower customers with options, knowledge and choice, delivering a consistent and frictionless experience, thereby improving customer satisfaction.
- Provide accurate, real-time, network-wide inventory visibility and availability across all channels.
- Optimize order fulfillment, taking into accounts costs, capacity, time, and other business parameters.
- Drive rapid innovation for customer-facing services, while modernizing the tech stack.
“As part of our Interconnected Retail strategy, we prioritize customer satisfaction and continuously evaluate our processes to enhance the customer experience,” said Nils Hornbach, member, Management Board, HORNBACH Baumarkt AG. “Our internal assessment revealed the need for a further development to improve order management across channels and provide a seamless omni-channel purchasing journey. After a thorough vendor evaluation, we selected Blue Yonder for their specialized expertise and market-leading order decisioning capabilities. Their architecture and technology ensure rapid time-to-value, scalability and performance, making Blue Yonder our preferred choice to support our digital transformation journey. This will give us an advantage in inventory availability and fulfillment, that will create high value for our customers. We look forward to collaborating with the Blue Yonder team.”
Blue Yonder’s flexible microservices-based solutions approach, embedded with machine learning (ML) and artificial intelligence (AI), will help HORNBACH Baumarkt to optimize the entire omni-channel customer journey, starting with an engaging customer experience through efficient order fulfillment. The retailer will also be able to accelerate its in-store and digital business to gain an advantage through a model that supports rapid implementation.
“HORNBACH Baumarkt is leading a game-changing transformation, focused on customer centricity and we are proud to welcome them among our customers,” said Gael Ramaen, vice president, EMEA Retail, Blue Yonder. “Blue Yonder Order Management solutions are engineered to scale, perform and operate under the highest volumes seen on the market. It can transform order management with an augmentative, composable approach, which delivers rapid time-to-market. We cannot wait to support HORNBACH Baumarkt in speeding their ongoing digital transformation.”
Additional Resources:
- Solution Sheet: Inventory Availability and Order Optimization
- E-book: Microservices: Your Next Big Move Just Got Smaller
- Learn more about Blue Yonder Order Management microservices
About HORNBACH Holding
HORNBACH is an independent, family-run, and publicly listed major company that generated net revenue of 6.2 billion euros in the 2023/24 fiscal year (balance sheet date: 29 February 2024). This makes the HORNBACH group one of the five largest home improvement and garden retailers in Europe. Founded in 1877, HORNBACH is the only company in the home improvement industry with a history spanning six generations. The company currently operates 169 home and garden centers, two specialist stores, and online shops in nine European countries. The sales concept and product range are particularly geared to the needs of project customers and professionals. HORNBACH guarantees its customers permanently low prices, making it the price leader in the industry. The company’s high quality of advice and excellent service have been recognized in numerous independent tests and studies. With pioneering achievements such as the first combined home and garden center (1968), the first megastore (1980), and the first home center with a drive-in facility (2003), HORNBACH is continually at the forefront of innovation. For decades, HORNBACH has been regarded as a job creator, with more than 25,000 employees now contributing to the company’s success. HORNBACH Holding
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Retailers, manufacturers and logistics service providers worldwide rely on Blue Yonder to optimize and accelerate their supply chain from planning through fulfillment, delivery, and returns. Blue Yonder’s AI-driven supply chain platform and multi-enterprise, multi-tier network enable more accurate forecasting and dynamic management of capacity, inventory and transport. Blue Yonder helps businesses navigate modern supply chain complexity and volatility with more resilient, sustainable supply chains to delight customers, scale profitably, and run flawlessly. www.blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240919416372/en/
Contacts
Blue Yonder Corporate Communications:
mediarelationsteam@blueyonder.com
U.S.: +1 480-308-3037
EMEA: +39 335 7849149
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom